CG Oncology leads five biotech readouts, Aclaris trial fails
Alpha Vantage · kalkine.ca · · AI-summarised by FinFlash
CG Oncology (NASDAQ:CGON) posted the strongest of five biotech clinical readouts, with its Phase 3 bladder cancer trial showing a 68% lower risk of recurrence and driving a significant stock gain. Aclaris Therapeutics (NASDAQ:ACRS) fell after its Phase 2 eczema trial missed its primary endpoint, while Lexeo, Helus Pharma and Alpha Tau delivered mixed results.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.